Cardiology in Michigan

Ehmet Health commercializes advanced medical device technology focused on precision radiotherapy solutions for cancer treatment. The company develops unified radiotherapy platforms designed to make cancer care more accessible, reliable, and efficient for healthcare providers. Their product portfolio includes Koda One, a proton therapy system with multi-room scalability and modular design for particle beam therapy delivery, and MammoKnife, a dedicated breast radiotherapy system featuring rotational LINAC technology with self-shielded design. Both systems emphasize organ-at-risk sparing, dose homogeneity, and improved patient outcomes while addressing the clinical and operational needs of modern cancer centers.

KEGO Corporation is a B2B medical equipment and supplies distributor headquartered in Clinton Township, Michigan. The company operates as a wholesaler and reseller of medical devices, home care products, and clinical consumables across multiple therapeutic categories. Product portfolio includes CPAP therapy systems and accessories (chinstraps, tubing, nasal cannulas), sleep study and polysomnography (PSG) equipment, neurology diagnostic supplies (EMG/NCS electrodes), respiratory therapy products (oxygen regulators, delivery tubing, cannulas), mobility aids (walkers, rollators, grab bars, transfer benches), activities of daily living (ADL) equipment (reachers, magnifiers, assistive devices), rehabilitation and physical therapy supplies (exercise equipment, gait belts, positioning discs), sleep and comfort products including the SleepAngel line (medical-grade pillows and positioners with PneumaPure filtration technology designed for HAI prevention), and wound/infection control consumables. KEGO also distributes the Parsons brand portfolio of mobility and ADL products following the November 2024 acquisition of Parsons ADL. The company serves hospitals, clinics, home health agencies, and long-term care facilities. Products are sourced from manufacturers including Salter Labs (respiratory consumables), CPAPology (CPAP accessories), and various specialty suppliers. KEGO operates a B2B e-commerce platform requiring account registration for pricing and order placement. No explicit regulatory certifications (FDA 510(k), ISO 13485, CE marking) are mentioned in available content.

AVAcore Technologies develops innovative perioperative patient warming and neurovascular therapy devices. The company's flagship product, warmUP™, is an FDA-cleared 510(k) non-invasive fluid-based patient warming system designed to maintain normothermia during surgical procedures and recovery. The device features a closed-loop architecture with a patient-attached disposable arm warming sleeve that decouples from the base unit, enabling seamless patient transfer from preoperative through recovery phases without disrupting operating room airflow. warmUP™ incorporates triple-redundancy burn-prevention controls and eliminates forced-air contamination risks associated with traditional warming systems. The system is engineered for cost-efficiency, utilizing a single universal adult sleeve per surgical case to reduce supply chain complexity and inventory SKU proliferation. AVAcore is also developing combinational therapies leveraging proprietary vasodilation technology for acute migraine and pain management, currently under development and not yet FDA cleared. The company targets perioperative and acute care markets, with regulatory clearance under FDA 510(k) (K040911) and patent protection under U.S. Patents 8,603,150 and 9,463,134. Products are restricted to sale by or on the order of a physician under federal law.

TheraBionic Inc. is an innovative medical device company specializing in cancer treatment through patented tumor-specific radiofrequency technology. The company manufactures the TheraBionic P1 device, an FDA-approved therapeutic system for advanced hepatocellular carcinoma (HCC)—the most common form of liver cancer—in patients who have failed first and second-line therapies. The TheraBionic P1 delivers amplitude-modulated radiofrequency electromagnetic fields (27.12 MHz) via a spoon-shaped antenna placed on the tongue, enabling systemic delivery of low-level, tumor-specific frequencies from head to toe. Clinical studies spanning over two decades demonstrate efficacy in tumor shrinkage, blocking new cancer cell growth, and improving overall survival rates. The device is compact, portable, and notably free of the debilitating side effects associated with conventional chemotherapy and other cancer treatments. TheraBionic's technology represents a breakthrough in non-toxic, systemic targeted therapy for difficult-to-treat cancers.